Advanced Practice Providers Oncology Summit

ONLINE ON DEMAND CE COURSES IN ONCOLOGY

Oncology 102: An In-Depth Hematology and Oncology Review for Advanced Practice Providers - 2024

The demand for cancer care is expected to increase by 40% over the next six years; however, ASCO is projecting a shortage of more than 2,200 oncologists by 2025. To meet the cancer care needs of all patients, advanced practice providers (APPs), whose education and training focus on health promotion, disease prevention, and primary care medical management, have been increasingly sought-after to fill this shortage. However, many new APPs have little background and training in oncology. As a result, oncology practices need to provide new staff with an onboarding program to help further their knowledge of hematology and oncology. To assist APPs in their new careers in oncology-based practices, Horizon CME, in partnership with APAO, has developed “Oncology 102: An In-Depth Hematology and Oncology Review for Advanced Practice Providers.” In this two-and-a-half-day virtual program, clinicians will gain a greater understanding of cancer treatment, cancer therapies, side effects, supportive care strategies, palliative care, and more. Expert faculty will provide a detailed review of treatment strategies for hematologic disorders and solid malignancies. Participation in the program will allow APPs to build upon the foundational knowledge acquired in Oncology 101 and provide APPs with a deeper understanding of the cancer treatment strategies they need to support and care for cancer patients as part of the multidisciplinary oncology care team.

(Course access available through December 28, 2024)

Registration

$125

REGISTER TODAY!

Target Audience

This activity is intended for oncology nurse practitioners, physician assistants, nurses, nurse navigators, medical assistants, and other healthcare providers involved in the care of cancer patients.

Faculty

PLANNING COMMITTEE

Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN

Nurse Practitioner Department of Hematology and Medical Oncology - Cleveland Clinic 

Beth Sandy, MSN, CRNP

Nurse Practitioner, Thoracic Medical Oncology Abramson Cancer Center, University of Pennsylvania

Ryan Beechinor, PharmD, BCPS, BCOP

Clinical pharmacist UC Davis Comprehensive Cancer Center San Francisco, CA

Leigh Ann Childress MSN, NP, AOCNP

Director of Advanced Practice Clearview Cancer Institute Huntsville, AL

Danielle Roberts PA-C

Physician assistant with the Bone Marrow Transplant team Winship Cancer Institute of Emory University Atlanta, GA

PRESENTING FACULTY

Jennie M. Goble, PA-C

Instructor in Medicine - Mayo Clinic Rochester, MN

Sandra Cuellar Puri, PharmD, BCOP

Clinical Oncology Pharmacist University of Illinois College of Pharmacy Chicago, IL

Jennifer Murphy, PharmD, BCOP, BCPS

Senior Pharmacist UCD Health, Oncology & Investigational Drug Service San Francisco, CA

Ellen Marin, PA-C

Physician Assistant Winship Cancer Institute of Emory University Atlanta, GA

Meredith Beaton, MSN, RN, AG-ACNP

Nurse Practitioner UCHealth Anschutz Aurora, CO

Jessica Walchonski, PA-C

Physician Assistant UCLA Health Los Angeles, CA

Kathleen Boyle, DScPAS, PA-C

Physician Assistant Dana-Farber Cancer Institute Boston, MA

Linda M. Perry, PA-C

Physician Assistant Hematology Perelman Center for Advanced Medicine Philadelphia, PA

Grace Baek, PharmD, BCOP

Clinical Pharmacist, Hematology/Oncology Fred Hutchinson Cancer Center Seattle, WA

Patricia Mangan, RN, MSN, CRNP

Nurse Lead, Hematologic Malignancies Program Abramson Cancer Center, University of Pennsylvania Philadelphia, PA

Laura Wood, RN, MSN, OCN

Nurse Cleveland Clinic, Taussig Cancer Center Cleveland, OH

Michael Lai, ARNP

Nurse Practitioner Fred Hutchinson Cancer Center Seattle, WA

Korie Bigbee DNP

Nurse Practitioner Specialist Kaiser Permanente at City of Hope Duarte CA

Heather Koniarczyk, MSN, APRN-CNP, AOCNP

Adult Nurse Practitioner Cleveland Clinic -Taussig Cancer Institute Cleveland, OH

Lisa Nodzon PhD, APRN, AOCNP

Nurse Practitioner H. Lee Moffitt Cancer Center and Research Institute Tampa, FL

Rasheda Persinger MS, AGNP-C, AOCNP

Lead Medical Oncology Nurse Practitioner Johns Hopkins Sibley Memorial Hospital Washington, DC

Alicia M. Rigby MSN, RN, APRN, AOCNP

Nurse Practitioner UC Davis Cancer Center Sacramento, CA

Tanya Uritsky PharmD, BCPP

Opioid Stewardship Coordinator University of Pennsylvania (HUP) Philadelphia, PA

Grace Cherry, NP

Nurse Practitioner UCLA Health Los Angeles, CA

Suzanne McGettigan CRNP

Oncology Nurse Practitioner and Clinical Manager of Advanced Practice Providers and Nursing Perelman Center for Advanced Medicine, Abramson Cancer Center Philadelphia, PA

Bridget Harr CNP

Nurse Practitioner Cleveland Clinic Cleveland, OH

FINANCIAL DISCLOSURES & CONFLICTS OF INTEREST

DISCLOSURES:

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Horizon CME (HCME) ensures that continuing education activities are balanced, independent, objective, and scientifically rigorous.

All persons in a position to influence the content of an accredited continuing education activity provided by Horizon CME are required to disclose to HCME any relevant financial relationships with ineligible companies within the past 24 months. All reported relevant financial relationships have been mitigated by Horizon CME.

 

Faculty, Authors, and Content Developers Disclosures:

  •  Rasheda Persinger, MS, AGNP-C, AOCNP discloses Advisory Board with AstraZeneca but that relationship has ended and Speaker’s bureau with Guardant and Astra Zeneca and Advisory Boards, Consulting Fee’s with AstraZeneca during the past 24 months.
    •    Sandra Cuehllar, PharmD, BCOP, FHOPA, FASHP discloses speaker’s bureau with Mirati and Advisory Board with Genetech during the past 24 months.
    •    Suzanne McGettigan, CRNP discloses Speaker’s Bureau with Regeneron, BMS, Pfizer, and Consulting Fee’s with Merck during the past 24 months.
    •    Rachel Frankenthal, PA-C discloses Advisory Boards with ImmunoGenX, and GSK but that relationship has ended during the past 24 months.
    •    Laura S. Wood, RN, MSN, OCN discloses speaker’s bureau with AVEO, BMS, EMD Serono, Exelixis, Merck, Pfizer during the past 24 months.
    •    Faith Mutale, DNP, CRNP discloses Speaker’s Bureau, Services for Promotional purposes with Merck, Helsinn, Consulting Fee’s with Merck, Pfizer, Helsinn, and Advisory Board with Pfizer during the past 24 months.
    •    Donna Catamero, ANP-BC, OCN, CCRC disclosed Speaker Bureau with BMS and GSK but that relationship has ended, Advisory Boards with Janssen Phar maceutical, Legend Biotech and Consulting Fee’s with BMS during the past 24 months.
    •    Amy Goodrich, RN, MSN, CRNP discloses Advisory Board with BeiGene, Abbvie, AstraZeneca, Epizyme, Janssen, Sano during the past 24 months.

Planners:

  •  Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN discloses consulting fee’s with Janssen, Sanofi, GSK, Pfizer during the past 24 months. 
    •    Beth Sandy, MSN, CRNP discloses speaker’s bureau with Merck, Amgen, Astra Zeneca, Lilly, Advisory Board with Takeda, Jazz, Janseen and Consulting Fee with Abbvie during the past 24 months.
    •    Leigh Ann Childress, MSN, NP, AOCNP discloses Advisory Board with Janssen but that relationship has ended and Speaker’s Bureau with AstraZeneca , Seagen , Amgen , Merck during the past 24 months.
    •    Ryan Beechinor, PharmD, BCPS, BCOP discloses current consulting fee’s with IQVIA, Cempra, ORM, Aptitude, Dedham and had contracted research with NIH and COG but that relationship has ended during the past 24 months.
    •    Beth Sandy, MSN, CRNP discloses speaker’s bureau with Merck, Amgen, Astra Zeneca, Lilly, Advisory Board with Takeda, Jazz, Janseen and Consulting Fee with Abbvie during the past 24 months.
    •    Rachel Frankenthal, PA-C discloses Advisory Boards with ImmunoGenX, and GSK but that relationship has ended during the past 24 months.